UP!

IVC $0.66

IVC target price
0.66
0
0
Invacare Corporation
Type
Public company
Traded as NYSE: IVC
S&P 600 Component
Founded 1885
Headquarters Elyria, Ohio, United States
Number of locations
30
Area served
80+ countries
Key people
Matthew E. Monaghan, CEO
Products Non-acute medical equipment
Services medical equipment,respiratory, wheelschairs,position beds,
Revenue IncreaseUS$1.8 billion(FY 2011)
Total assets IncreaseUS$1.3 billion(FY 2011)
Total equity DecreaseUS$626.5 million(FY 2011)
Number of employees
5900+
Website www.invacare.com

Invacare Corporation (NYSE: IVC) is an American manufacturer and distributor of non-acute medical equipment including wheelchairs, mobility scooters, walkers, pressure care and positioning, as well as respiratory products. Headquartered in Elyria, Ohio, the company currently distributes its product to more than 80 countries around the world.

The history of Invacare can be traced back to 1885 when the Worthington Company began to produce a wide range of wheelchairs. The product lines were expanded several times, but its main focus remained in wheelchairs.

In the 1970s, Invacare was owned by Technicare, a Cleveland medical device manufacturer. With Mal Mixon as its Vice President of Marketing, the company branched into the field of diagnostic imaging. Later in 1978, Technicare was acquired by Johnson & Johnson who subsequently put Invacare up for sale. Driven by the wish of running his own firm, Mal Mixon expressed interest in buying Invacare. Because of financial constraint, Mixon had to borrow $4.3 million and raise another $2.5 million in order to buy Invacare at $7.8 million. The transaction closed on December 28, 1979.

Today, through numerous acquisitions, Invacare has grown into a $1.8 billion medical product company, supplying over 25,000 medical equipment providers with its product and distributing them to more than 80 countries around the world.

In 2012, Invacare entered into a Consent Decree with the Federal Government regarding certain products and facilities.

By 2013, the FDA had accepted two certification reports by an independent auditor, making progress toward removing the consent decree. In 2015, after a follow up inspection, the agency informed Invacare that more work was required in both the company’s controls over its design process and design history as outlined in report two.

Although the third party auditor had submitted a third and final certification report whose acceptance could have lifted the consent decree, no review could be done on that report until the discrepancies noted in report two had been resolved.

In April 2017, the agency informed that company that it had accepted the revised second certification report allowing Invacare to resume design work in its Elyria, OH facility. The company is awaiting review and acceptance of the third certification report.

On September 27, 2007, A. Malachi Mixon was conferred the Harvard Business School's highest honor, the Alumni Achievement Award, by Dean Jay O. Light. The award was also given to Ayala Corp. chair Jaime Augusto Zobel de Ayala, Martin Sorrell, Donna Dubinsky and Hansjorg Wyss of Synthes.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-10-25 Future report Set alerts
Q2 2022 2022-08-08 -0.62 -0.62
Q1 2022 2022-05-09 -0.69 -0.69
Q4 2021 2022-03-08 0.08 0.08
Q3 2021 2021-10-27 -0.12 -0.12
Q2 2021 2021-08-04 -0.28 -0.28
Q1 2021 2021-05-05 -0.36 -0.36
Q4 2020 2021-02-10 -0.10 -0.10
Q3 2020 2020-10-29 -0.10 -0.10
Q2 2020 2020-08-05 -0.21 -0.21

Ratings

2014-10-24 Upgrade KeyBanc Hold to Buy $17.00
2014-04-09 Initiated Coverage KeyBanc Hold
2013-10-24 Downgrade Sidoti Buy to Neutral
2013-09-24 Initiated Coverage CJS Securities Outperform
2010-06-02 Initiated CL King Accumulate $30
2010-03-11 Downgrade Soleil Buy to Hold $30
2008-07-28 Upgrade Stifel Nicolaus Hold to Buy $27
1970-01-01
2014-10-24 Upgrade KeyBanc Hold to Buy $17.00
2014-04-09 Initiated Coverage KeyBanc Hold
2013-10-24 Downgrade Sidoti Buy to Neutral
2013-09-24 Initiated Coverage CJS Securities Outperform
2010-06-02 Initiated CL King Accumulate $30

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In IVC 0 funds of 2213 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
RICHEY JOSEPH B II Senior Vice President 60.86%  (660200) IVC /
Monaghan Matthew E. President and CEO 24.39%  (264596) INCR / IVC /
BLOUCH GERALD B President and CEO 20.91%  (226813) IVC /
Gudbranson Robert K Sr. VP and CFO 11.85%  (128557) IVC /
WEBER WILLIAM M 6.60%  (71643) IVC /
Childers Dean J. SVP & GM, North America 4.62%  (50077) IVC /
LaPlaca Anthony Sr. VP and General Counsel 4.34%  (47124) IVC /
Shah Baiju R. 4.33%  (46941) IVC /
Leneghan Kathleen P. Senior VP and CFO 3.85%  (41717) IVC /
HARRIS C MARTIN 3.78%  (41023) CL / HSTM / IVC / TMO /
DELANEY MICHAEL F 3.66%  (39742) IVC /
Ledda Ralf Sen VP/GM-EUR,Mid East&Africa 3.46%  (37536) IVC /
SLANGEN LOUIS F J Senior Vice President 3.25%  (35303) IVC /
LaPorte Dale C 3.00%  (32585) IVC /
Remmers John Sr. VP Global Supply Chain&Eng 2.94%  (31895) IVC /
NASTAS CLIFFORD D 2.79%  (30246) IVC / MASC /
Stumpp Patricia A. Senior VP, Human Resources 2.69%  (29231) IVC /
Jones James L 2.55%  (27627) IVC /
Gibeley Marc M. 2.13%  (23119) IVC /
Will Carl E. Sen. VP, Global Commercial Ops 1.76%  (19038) AIT / IVC /
MERRIMAN MICHAEL J 1.71%  (18538) IVC / NDSN / OMN / RGS /
ALEXANDER SUSAN H 1.67%  (18153) BIIB / IVC /
Sutherland Gordon SVP & GM, EMEA 1.61%  (17468) IVC /
Robb Charles S. 1.52%  (16481) IVC /
Tauscher Ellen O. 1.38%  (15014) EHTH / EIX / IVC / SEAS /
MOORE DAN T III 1.37%  (14861) IVC / PKOH /
Bodem Barbara W. 1.08%  (11728) IVC /
MIXON AARON MALACHI III Chairman 0.39%  (4254) IVC / PKOH / SHW /